Misonix Announces New Distribution Agreement For Denmark

           Misonix Announces New Distribution Agreement For Denmark

PR Newswire

FARMINGDALE, N.Y., April 2, 2013

FARMINGDALE, N.Y., April 2, 2013 /PRNewswire/ -- Misonix, Inc. (NasdaqGM:
MSON), a surgical device company that designs, manufactures and markets
innovative therapeutic ultrasonic products worldwide for spine surgery,
skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, has entered into a new,
three year, exclusive distribution agreement with Maersk-Andersen AS, based in
Randers, Denmark, for the distribution of the Misonix® BoneScalpel™ Ultrasonic
Bone Cutting System. The agreement provides Maersk-Andersen with the right to
sell throughout Denmark. Included in the agreement are annual minimum
purchase requirements. Product training has been completed and open market
sales have commenced.

Maersk-Andersen, known for their focused market presence in neuro, spine and
other orthopedic surgeries, is well prepared and strategically well positioned
to successfully introduce high tech products, like the BoneScalpel, to the
Danish market. Their commitment to clinical education and product service is
well known and separates them from the competition.

The Misonix BoneScalpel is a novel ultrasonic osteotome (bone cutting device)
used for safe, tissue-selective bone dissection that encourages non-fragmented
bone removal and refined osteotomies while sparing elastic soft tissue
structures. Most users report that the surgical field is relatively clean and
bloodless. Loss of viable bone is minimal and controllable. The BoneScalpel
has been used extensively for bone removal in spine surgery and maxillo-facial
reconstructive surgery.

"It is our pleasure to add Maersk-Andersen to our distribution organization in
Europe; their presence in a sophisticated healthcare market like Denmark could
add measurably to our sales success. Their history of successfully
introducing cutting edge products to the Danish market is well known to us,"
said Michael A. McManus, Jr., President and Chief Executive Officer of
Misonix.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.

                                         Investor Relations
                                         Contacts
Misonix Contact:                    Lytham Partners, LLC
Richard Zaremba        Robert Blum, Joe Dorame, Joe Diaz
631-694-9555  602-889-9700
invest@misonix.com    mson@lythampartners.com

SOURCE Misonix, Inc.
 
Press spacebar to pause and continue. Press esc to stop.